RenovoRx reports 2025 revenue of $1.1M from RenovoCath; net loss $11.2M; cash $13M after $10M financing

RenovoRx, Inc.

FY2025 revenue $1.1M vs $43K in 2024; first full year of RenovoCath commercialization; cost of revenue $327K, gross profit $796K.
Net loss $11.2M ($0.32 diluted EPS) vs $8.8M ($0.40) in 2024; R&D spend $6.3M, SG&A $7.0M.
Phase III TIGeR-PaC trial: 104 patients randomized (target 114), 72 deaths; enrollment completion expected mid-2026, final data 2027.
12 U.S. cancer centers actively using RenovoCath as of Feb 2026; 33 centers in pipeline; $400M peak U.S. TAM for device.
Appointed Mark Voll as CFO in Feb 2026; closed $10M private placement (net $9.2M) on Mar 20, 2026; cash $13M on hand.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RenovoRx, Inc. reported fiscal year ended December 31, 2025 results: revenue $1.1 million.

Period: fiscal year ended December 31, 2025
Revenue: $1.1 million
Result: reported results

Exact text from the filing

For the year ending December 31, 2025, the Company generated $1.1 million in revenue from RenovoCath sales, driven by both new cancer centers adopting the device and repeat orders from existing customers.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

RenovoRx, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-013653

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.